Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients With Active Psoriatic Arthritis: Week 52 Results From a Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 2b/3 Study

izokibep (ABY-035) - Affibody

https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQnIatftDbYekureUVZE1EGBRU-e07HqIJqINWyF4PMJW0

Philip J. Mease1; Frank Behrens2; Alan Kivitz3; Edit Drescher4; Piotr Adrian Klimiuk5; Howard Sofen6; Nehad Soloman7; Shephard Mpofu8; Fredrik Y Frejd9; Peter C. Taylor10

Mar 18, 2026